Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 789-797

  Fukudo, Masahide ^a   Yano, Ikuko ^a   Shinsako, Keiko ^a   Katsura, Toshiya ^a   Takada, Yasutsugu ^b   Uemoto, Shinji ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Bayesian; Dose optimization; Living donor liver transplantation; Pharmacokinetics; Tacrolimus

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; BAYES THEOREM; BILE DUCT ATRESIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MAINTENANCE DRUG DOSE; MALE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BAYES THEOREM; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TACROLIMUS;

EID: 67650472812     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009333853     Document Type: Article

References (28)

1. Strong RW Living-donor liver transplantation: an overview. J Hepatobiliary Pancreat Surg. 2006 ; 13: 370-377. (Pubitemid 44480237)
2. O'Grady JG, Burroughs A., Hardy P., Elbourne D., Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002 ; 360: 1119-1125.
3. Staatz CE, Tett SE Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004 ; 43: 623-653. (Pubitemid 38981845)
4. Yasuhara M., Hashida T., Toraguchi M., et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc. 1995 ; 27: 1108-1110.
5. Sam WJ, Aw M., Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol. 2000 ; 50: 531-541. (Pubitemid 32010014)
6. García Sánchez MJ, Manzanares C., Santos-Buelga D., et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet. 2001 ; 40: 63-71. (Pubitemid 32182114)
7. Staatz CE, Willis C., Taylor PJ, Lynch SV, Tett SE Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003 ; 9: 130-137. (Pubitemid 36204563)
8. Antignac M., Hulot JS, Boleslawski E., et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005 ; 61: 409-416. (Pubitemid 41569318)
9. Zahir H., McLachlan AJ, Nelson A., McCaughan G., Gleeson M., Akhlaghi F. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005 ; 27: 422-430. (Pubitemid 41098815)
10. Lee JY, Hahn HJ, Son IJ, et al. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy. 2006 ; 26: 1069-1077. (Pubitemid 44167815)
11. Li D., Lu W., Zhu JY, Gao J., Lou YQ, Zhang GL Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007 ; 32: 505-515. (Pubitemid 47404287)
12. Proost JH Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther. 1995 ; 33: 531-536.
13. Irtan S., Saint-Marcoux F., Rousseau A., et al. Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007 ; 29: 96-102. (Pubitemid 46279882)
14. Djebli N., Rousseau A., Hoizey G., et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet. 2006 ; 45: 1135-1148. (Pubitemid 44631392)
15. Le Meur Y., Bachler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 ; 7: 2496-2503. (Pubitemid 47566324)
16. Macchi-Andanson M., Charpiat B., Jelliffe RW, Ducerf C., Fourcade N., Baulieux J. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit. 2001 ; 23: 129-133. (Pubitemid 32240139)
17. Fukatsu S., Yano I., Igarashi T., et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001 ; 57: 479-484.
18. Fukudo M., Yano I., Fukatsu S., et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003 ; 42: 1161-1178. (Pubitemid 37357651)
19. Cogill JL, Taylor PJ, Westley IS, Morris RG, Lynch SV, Johnson AG Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem. 1998 ; 44: 1942-1946. (Pubitemid 28405760)
20. Sheiner LB, Beal SL, Rosenberg B., Marathe VV Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979 ; 26: 294-305. (Pubitemid 10194671)
21. Beal SL, Sheiner LB NONMEM User's Guide. San Francisco, Calif: NONMEM Project Group, University of California at San Francisco ; 1992.
22. Sheiner LB, Beal SL Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 ; 9: 503-512.
23. Hebert MF Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997 ; 27: 201-214. (Pubitemid 27417873)
24. Hashida T., Masuda S., Uemoto S., Saito H., Tanaka K., Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001 ; 69: 308-316. (Pubitemid 32477071)
25. Masuda S., Goto M., Fukatsu S., et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther. 2006 ; 79: 90-102. (Pubitemid 43069581)
26. Fukudo M., Yano I., Yoshimura A., et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008 ; 18: 413-423.
27. Willis C., Staatz CE, Tett SE Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit. 2003 ; 25: 158-166. (Pubitemid 36373422)
28. D'Argenio DZ Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981 ; 9: 739-756. (Pubitemid 12184821)